Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Géczi, Lajos; Bodoky, György; Rokszin, György; Fábián, Ibolya; Torday, László

Géczi, Lajos; Bodoky, György; Rokszin, György; Fábián, Ibolya; Torday, László.

Affiliation

Géczi L; Urogenital Tumors and Clinical Pharmacology Department, National Institute of Oncology, Ráth György u. 7-9, 1122, Budapest, Hungary. gelajos@oncol.hu.
Bodoky G; Department of Oncology, Szent László Hospital, Albert Flórián út 5, 1097, Budapest, Hungary.
Rokszin G; RxTarget Ltd, Bacsó Nándor út 10, 5000, Szolnok, Hungary.
Fábián I; RxTarget Ltd, Bacsó Nándor út 10, 5000, Szolnok, Hungary.
Torday L; University of Veterinary Medicine, István út 2, 1078, Budapest, Hungary.

Pathol Oncol Res ; 26(4): 2201-2207, 2020 Oct.

Article in En | MEDLINE | ID: mdl-32291570

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Renal Cell/mortality; Kidney Neoplasms/mortality; Aged; Aged, 80 and over; Axitinib/administration & dosage; Carcinoma, Renal Cell/drug therapy; Carcinoma, Renal Cell/pathology; Everolimus/administration & dosage; Female; Follow-Up Studies; Humans; Kidney Neoplasms/drug therapy; Kidney Neoplasms/pathology; Male; Middle Aged; Prognosis; Retrospective Studies; Sunitinib/administration & dosage; Survival Rate

Key words

Axitinib; Metastatic renal cell carcinoma; Overall survival; Sequential therapy; VEGF inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Pathol Oncol Res Journal subject: NEOPLASIAS / PATOLOGIA Year: 2020 Type: Article Affiliation country: Hungary

Fulltext

XML

PubMed Links

Search on Google